Scarica l'app Stockscreener
2.18
14.00%
-0.355
Innate Pharma Adr Borsa (IPHA) Ultime notizie
Innate Pharma Secures €30M, Extends Cash Runway Into 2028 - sharewise.com
Unusual volume stocks are being observed in Wednesday's session. - ChartMill
FY2026 EPS Estimates for Innate Pharma Reduced by Analyst - MarketBeat
The trading volume of these stocks is deviating from the norm in today's session. - ChartMill
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Innate Pharma stock price target raised to $7 by H.C. Wainwright on Sobi deal - Investing.com
Innate Pharma plans phase 3 trial, names new medical officer By Investing.com - Investing.com South Africa
Innate Pharma plans phase 3 trial, names new medical officer - Investing.com
Innate Pharma partners with Sobi on lacutamab development - Investing.com
Innate Pharma partners with Sobi on lacutamab development By Investing.com - Investing.com South Africa
Innate Pharma completes enrollment in IPH4502 phase 1 study - Investing.com
Innate Pharma completes enrollment in IPH4502 phase 1 study By Investing.com - Investing.com South Africa
IPHA Q1 2026 Earnings: Significant EPS Miss on R&D InvestmentsEPS Surprise History - po-news-eg.net
Form 13G Innate Pharma SA For: 22 June By Investing.com - Investing.com South Africa
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company - Benzinga
IPHAInnate Pharma ADR Stock Price and Quote - Finviz
AUTLAutolus Therapeutics plc ADR Stock Price and Quote - Finviz
IPHA Technical Analysis | Trend, Signals & Chart Patterns | INNATE PHARMA SA-SPONS ADR (NASDAQ:IPHA) - ChartMill
Earnings call transcript: Innate Pharma Q1 2026 beats earnings expectations By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q1 2026 beats earnings expectations - Investing.com
Ascentage Pharma: Buy Rating Reiterated on Advancing CML/ALL Pipeline and DCF-Supported Unchanged $48 Price Target - TipRanks
Innate Pharma Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Innate Pharma Q1 2026 revenue beats forecasts By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q1 2026 revenue beats forecasts - Investing.com
Unusual VolumeStock ScreenerNews - Finviz
Innate Pharma reports interim lung cancer trial results By Investing.com - Investing.com South Africa
Innate Pharma reports interim lung cancer trial results - Investing.com
HC Wainwright Decreases Earnings Estimates for Innate Pharma - MarketBeat
Top GainersStock ScreenerSnapshot - Finviz
Innate Pharma (IPHA) outlines oncology pipeline and key risks in Form 20-F - Stock Titan
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Sees Large Decline in Short Interest - MarketBeat
Innate Pharma Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Innate Pharma Q4 2025: Strategic Focus Amid Cost Management By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q4 2025: Strategic Focus Amid Cost Management - Investing.com India
Innate Pharma reports 55% revenue drop, expects cash runway until end of Q3 2026 - Investing.com
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Short Interest Update - MarketBeat
Innate Pharma stock initiated with buy rating at BTIG on oncology pipeline By Investing.com - Investing.com India
Innate Pharma stock initiated with buy rating at BTIG on oncology pipeline - Investing.com
NASDAQ New 52-Week Highs And Lows - Moomoo
Innate Pharma (NASDAQ:IPHA) Shares Up 3.6%Here's What Happened - MarketBeat
Innate Pharma (NASDAQ:IPHA) Shares Up 3.6% – Here’s What Happened - Defense World
Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference - ChartMill
Innate Pharma (NASDAQ:IPHA) Stock Price Down 2.2%Should You Sell? - MarketBeat
Innate Pharma Q3 2025 slides: Lacutamab progress highlighted amid clinical advances - Investing.com
Innate Pharma stock soars after FDA clears path for Phase 3 trial - Investing.com
Lucid Capital Markets initiates coverage on Innate Pharma stock with Buy rating - Investing.com
Here's Why Inventiva (IVA) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Earnings call transcript: Innate Pharma’s Q2 2025 focus on strategic assets - Investing.com
Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook - Investing.com
Earnings call transcript: Innate Pharma Q4 2024 sees strategic advances By Investing.com - Investing.com South Africa
Let's take a look at the stocks that are in motion in today's session. - ChartMill
Stay updated with the stocks that are on the move in today's after-hours session. - ChartMill
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace
Innate Pharma (IPHA) Stock Forecast and Price Target 2026 - MarketBeat
Innate Pharma Announces Its Participation in Upcoming Investor Conference By Investing.com - Investing.com India
symbol__ Stock Quote Price and Forecast - CNN
Innate (IPHA) Gains as Blood Cancer Drug Gets Fast Track Tag - Nasdaq
What is the current Price Target and Forecast for Innate Pharma (IPHA) - Zacks Investment Research
Biophytis (BPTS) Share Price Today | Biophytis (BPTS) Live NSE/BSE - Value Research
Which Is a Better Investment, Novo Nordisk A/S (ADR) or Sanofi SA (ADR) Stock? - AAII
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):